Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors

被引：0
|
作者：
Castello, A. [1 ]
Rossi, S. [1 ]
Toschi, L. [1 ]
Lopci, E. [1 ]
机构：
[1] Humanitas Clin & Res Hosp, Rozzano, MI, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-024
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [31] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [32] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [33] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
    Abu Sabbah, Tanja
    Theurer, Sarah
    Baba, Hideo Andreas
    Lueong, Smiths
    Rashidi-Alavijeh, Jassin
    Hilser, Thomas
    Zaun, Yasmin
    Metzenmacher, Martin
    Pogorzelski, Michael
    Virchow, Isabel
    Pretzell, Ina
    Kostbade, Karina
    Treckmann, Jurgen
    Wiesweg, Marcel
    Schuler, Martin
    Kasper, Stefan
    Zaun, Gregor
    EUROPEAN JOURNAL OF CANCER, 2024, 210
  • [35] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
    Lau, Sally C. M.
    Le, Lisa W.
    Smith, Elliot Charles
    Chan, Sze Wah Samuel
    Ryan, Malcolm
    Brown, M. Catherine
    Hueniken, Katrina
    Eng, Lawson
    Patel, Devalben
    Chen, RuiQi
    Sung, Mike Ru
    Zer, Alona
    Bradbury, Penelope Ann
    Ohashi, Pamela S.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Liu, Geoffrey
    Leighl, Natasha B.
    Sacher, Adrian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
    Gray, Steven G.
    Cuffe, Sinead
    Finn, Stephen P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : E142 - E144
  • [38] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Wang, Yimin
    Han, Hedong
    Zhang, Fang
    Lv, Tangfeng
    Zhan, Ping
    Ye, Mingxiang
    Song, Yong
    Liu, Hongbing
    BRITISH JOURNAL OF CANCER, 2022, 127 (05) : 948 - 956
  • [39] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [40] Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels
    Kim, Leeseul
    Um, Taegyu
    Chae, Young Kwang
    Cho, Allen
    CANCER RESEARCH, 2023, 84 (06)
12345